NSA 2/28/19 HOSPW Migraine Management

February 28, 2019

Migraine Management: A Review of Pharmacotherapy Options

Speaker: Heidi Israel, PharmD

Primary care physicians are not familiar with the new KPHC migraine treatment algorithm. Aimovig is a new class CGRPR antagonist newly approved for migraine prevention. We want to provide education of this class of medication and proper use within Kaiser Permanente. 

To understand risks and benefits of the available treatment options. CGRPR antagonist only provide one or 2 fewer migraine days per month versus placebo, similar to the oral first-line therapies. 

Kaiser Napa Solano Area is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians.  The Kaiser Napa Solano Area designates this Live Activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Target Audience

Primary care physicians and other interested clinicians

Learning Objectives

Describe red flag symptoms of migraine

Explain criteria for migraine prophylaxis

Summarize restrictions for using Aimovig 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
Course opens: 
02/28/2019
Course expires: 
02/28/2019
Event starts: 
02/28/2019 - 12:30pm
Event ends: 
02/28/2019 - 1:30pm
Rating: 
0

Kaiser Napa Solano Area is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians.  The Kaiser Napa Solano Area designates this Live Activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™

Accreditation Period

Course opens: 
02/28/2019
Course expires: 
02/28/2019
Please login or register to take this course.